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Case RepoRt
One of the major drawbacks of multiple blood transfusions 
in patients with thalassemia is the risk of development of 
alloimmunization to various red cell antigens within blood 
group systems such as Rh, Kell, Duffy, and Kidd. The problem is 
greater in developing countries because of lack of awareness and 
insufficient availability of specific typing antisera and antibody 
screening panels owing to financial constraints. It is of utmost 
importance to provide D, C, c, E, e, and K phenotype-matched 
blood in multiply transfused patients with thalassemia. This can 
prevent the development of antibodies against these clinically 
significant antigens, as antibodies can cause severe acute or 
delayed hemolytic transfusion reactions and create difficulties 
in providing a crossmatch-compatible packed red blood cell 
unit. The policy should preferably be adopted irrespective of 
financial constraints as it will pave the way for better transfusion 
practices and reduce the risk of adverse reactions in patients who 
are transfusion dependent for survival. Immunohematology 
2012;28:45–8.
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Transfusion therapy forms the backbone of treatment for 
patients with thalassemia, especially in thalassemia major in 
which it may have to be instituted during infancy. However, a 
major drawback of multiple blood transfusions in such a patient 
subset is the risk of development of alloimmunization to various 
red blood cell (RBC) antigens within blood group systems 
such as Rh, Kell, Duffy, Kidd, and others. Various studies from 
India estimate this risk to be less than 10 percent.1,2 However, 
Michail-Merianou et al. reported the overall frequency of 
alloimmunization to be 18.9 percent among children with 
thalassemia and even higher, i.e., 25 percent, in children in 
whom transfusion therapy was initiated after their first year 
of life.3 To minimize the occurrence of this adverse event, the 
British Committee for Standards in Haematology (BCSH) 
recommends routine and extended phenotyping of multiply 
transfused patients like those with thalassemia for ABO, D, C, 
c, E, e, and K antigens.4 These antigens are immunogenically 
most potent and antibodies to these antigens are encountered 
in approximately two thirds of all cases of alloimmunization.4 
At our center, we strictly adhere to these BCSH guidelines. 
But in resource-poor centers, it may not always be possible to 
follow these guidelines, especially at peripheral centers, which 
may put the recipient at a higher risk of alloimmunization. 
Here, we report a 6-year-old child with thalassemia who was 
transfused with phenotype-matched blood since infancy and 
developed anti-K after receiving several transfusions outside 
our institution. To the best of our knowledge, there are only 
two case reports from India documenting this phenomenon.5,6
Case Report
A 6-year-old male child, blood group B, D+, had been 
diagnosed with thalassemia major at 13 months of age and 
was thereafter started on regular packed red blood cell (RBC) 
transfusions at 21-day intervals to maintain his hemoglobin at 
a level of 9 to 10 g/dL. His serum ferritin levels ranged between 
720 and 790 µg/dL. At family screening, it was found that the 
parents were carriers of thalassemia trait and his two siblings 
were normal. The patient was being transfused with ABO, D, 
C, c, E, e, and K compatible packed RBCs. He had received 
more than 50 RBC transfusions, with an average of 13 to 14 
transfusions per year. Two months before the incident reported 
here, his parents did not report for his regular transfusion, citing 
personal reasons. During this period, he received two packed 
RBC transfusions at a peripheral hospital. However, within 12 
days of his last transfusion, he returned to our institution with 
complaints of increasing pallor and yellowish discoloration of 
the urine and eyes. An antibody screen was performed on the 
patient’s blood sample along with an identification panel using 
commercially prepared RBCs (Dia Cell II, Bio-Rad, Haryana, 
India). The results of the antibody screen and identification 
panel confirmed the presence of anti-K in the patient’s serum. 
An auto control was negative at both saline and anti-human 
globulin phases. No reactivity was seen with dithiothreitol 
(DTT)-treated serum. This was expected, as Kell antibodies 
are known to be denatured by DTT. An extended phenotype of 
the patient’s RBCs revealed the phenotype as D+ C+ c– E– e+ 
K– k+ Jk(a– b+) Fy(a+b–) M+ N+ S– s+ and P1+. One PRBC 
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unit, group B, D+, and negative for E, c, and K, was issued to 
the patient and transfused uneventfully.
Discussion
In 1946, a new blood group antibody was identified in the 
serum of a woman, Mrs. Kelleher, that reacted with RBCs from 
her husband and her older child. The Kell blood group system 
has nearly 30 antigens; its two major antigens are K (Kell) and 
k (cellano). K is very immunogenic in stimulating antibody 
production, the sequence of immunogenicity being D > c > K 
> E > C > e.7,8 Kell blood group antigens are well developed at 
birth, as K appears at 10 weeks of gestation and k at 7 weeks. 
Antibodies to K may be produced as a result of immune 
stimulation, i.e., during transfusion and pregnancy. Clinically, 
it is very significant as these antibodies can cause hemolytic 
disease of the fetus and newborn and hemolytic transfusion 
reactions. Table 1 shows the prevalence of Kell blood group 
system phenotypes in various ethnic populations.8,9,10 Among 
north Indian blood donors, the prevalence of K is 5.68  percent.9 
Because of the low prevalence of K in the general population, 
anti-K may be missed during routine crossmatching but can 
be detected in an antibody screen.
In India, the incidence of alloantibodies in patients with 
thalassemia is 7 to 10 percent. Table 2 summarizes the various 
studies reporting the incidence of alloimmunization to Rh and 
Kell antigens in various thalassemia populations. Pradhan et 
al. found 7 patients among 100 patients with thalassemia to 
have RBC alloantibodies. Among these, three had anti-D and 
one each had anti-C, anti-C and anti-D, and anti-Fya. Another 
case demonstrated the presence of naturally occurring 
anti-N and anti-Leb with no patient showing a Kell antibody.1 
Recently, Gupta et al. reported development of alloantibodies 
in 11 thalassemia patients among 116 patients, with 3 patients 
showing anti-K. The most common antibody identified was 
anti-E in 4/116 (3.4%), followed by anti-K in 3/116 (2.6%), 
anti-Kpa in 2/116 (1.7%), and anti-Cw in 2/116 (1.7%) 
patients.2 Thakral et al. reported the development of anti K in 
a transfusion-dependent child with thalassemia.5 Arora et al. 
also recently reported the development of alloimmunization 
to both Rh and Kell system antigens (anti-C, -K)  in a young 
patient with thalassemia.6 In both these cases, the patient 
received ABO- and D-matched, crossmatch-compatible blood, 
but phenotyping for C, c, E, e, and K was not performed.
Our patient had been receiving ABO, D, C, c, E, e, and K 
antigen-matched blood since he was diagnosed at 13 months 
of age. However, after having received two transfusions at 
a peripheral center, the patient developed alloantibodies 
to K, which, in turn, led to clinical symptoms of anemia, 
jaundice, and decreased transfusion intervals as a result of the 
shortened survival of transfused cells. This can be attributed 
to transfusion of K-unmatched blood. At the peripheral center, 
an antibody screen was not performed, and crossmatch 
compatibility was tested at the saline phase only. This was 
because of a lack of expertise and adequate facilities.
Michail-Merianou et al. did not find a statistically 
significant difference in alloimmunization between unmatched 
blood (compatible for ABO and D) versus better-matched 
blood (compatible for ABO, D, C, c, E, e, and K) in transfusion 
recipients (23.4% vs. 14.3%).3 No significant difference was 
seen between unmatched and better-matched policies among 
children in whom transfusion therapy was started before 12 
months of age (9% vs. 5.2%). However, the difference was 
statistically significant when transfusion therapy was started 
after 12 months of age (38.7% vs. 18.9%, respectively). Among 
the alloimmunized recipients, nearly one fourth showed 
alloantibodies to K in an unmatched group vs. no one in the 
better-matched group. Michail-Merianou et al. thus concluded 
that the earlier transfusion therapy is initiated, the less is the 
likelihood of alloimmunization, probably owing to development 
of immune tolerance to repeated blood transfusions (induced 
by an immature immune response in children). Also, the 
frequency of transfusions is less in such patients. The authors 
strongly recommended prophylactic phenotype matching for 
at least Rh and K antigens as a transfusion policy for children 
with thalassemia when transfusion therapy is started after 12 
months of age. It is the view of these authors that if transfusion 
therapy is started before 12 months, the better-matched policy 
appears unnecessary.3
In a study from Iran involving 313 children, 12 
alloantibodies were seen in 9 children (2.87%), the most 
common being anti-D followed by anti-C and anti-E.11 In 
another study, among an Arab population, 57 (30%) of 190 
patients developed RBC alloantibodies, with anti-K being 
Table 1. Prevalence of Kell blood group system phenotypes in 
various ethnic populations
Phenotype 
Thakral et al9 (%) 
(n=1240)*
Nanu et al10 (%) 
(n=6334)† Whites (%)8 Blacks (%)8
K+k+ 5.68 4.04 8.8 3.5
K–k+ 94.32 95.96 91 96.5
K+k– 0 0 0.2 <0.1
Kp(a+b+) 0.95 ND 2.3 Rare
Kp(a–b+) 99.05 ND 97.7 100
*North Indian blood donors.
†Selected north Indian population.
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Alloimmunization to K
the most common clinically significant alloantibody in 41 
(72%) patients followed by anti-E in 26 (45.6%).12 A report 
describing patients with thalassemia who were predominantly 
of Asian descent found that 14 (22%) of 64 patients became 
alloimmunized, and erythrocyte autoantibodies developed in 
16 (25%) of the 64 patients, thereby causing severe  hemolytic 
anemia in 3 of 16 patients.13 In both these studies, the 
authors observed that a higher rate of alloimmunization is 
seen among patients with thalassemia transfused with non-
leukocyte-depleted blood compared with leukocyte-depleted 
blood. It has been hypothesized that the release of immune-
stimulatory antigens and soluble biological mediators from 
the residual leukocytes sensitizes the immune system of 
recipients and causes development of alloantibodies to foreign 
antigens. Martelli et al., using specialized techniques such as 
enzyme-linked immunosorbent assay, flow cytometry, and 
immunofluorescence, observed that nuclear matrix protein is 
released from apoptotic white blood cells during cold storage 
of RBC units. They suggested that this phenomenon might 
lead to antibody response in multiply transfused patients.15 
Further, it was observed that the rate of alloimmunization 
was higher in patients who had undergone splenectomy as 
compared with those who had not undergone this operation. 
It was postulated that patients without spleens are more prone 
to develop both alloantibodies and autoantibodies, and that 
antibody formation is prevented in the patients with intact 
spleens because of filtration of antigens in the spleen. In 
another study from Italy, 5.2 percent of the patients (74 of 1435 
patients) had clinically significant RBC alloantibodies against 
Rh, Kell, Kidd, and Duffy system antigens, in decreasing order 
of frequency.16
The provision of adequately matched, crossmatch-
compatible PRBCs to multiply transfused patients like those 
with thalassemia remains a major challenge in developing 
countries. Although these patients are at a considerable risk 
of developing antibodies to various foreign RBC antigens, this 
transfusion complication is underreported or underestimated. 
Thakral et al. attributed this to the relative lack of awareness, 
insensitive crossmatch techniques, and unavailability of 
antigen panels.5 In addition, the RBC panels used for antibody 
detection and identification may not represent the true 
antigen prevalence within our Indian population. The present 
case emphasizes the importance of providing phenotype-
matched blood and implementation of routine screening 
for alloantibodies to K in multiply transfused patients with 
thalassemia, as these can cause severe acute or delayed 
Table 2. Studies showing the incidence of alloimmunization to Rh and Kell antigens in various thalassemia populations
Authors, country Prevalence Extended Rh alloantibodies Kell alloantibodies Others
Pradhan et al., India1 7% Anti-D: 3%; anti-C,-D: 1%; 
anti-C: 1% 
None Anti-Fya: 1% 
anti-N,-Leb: 1%
Gupta et al., India2 9.5% Anti-E: 3.4%; anti-Cw: 1.7% Anti-K: 2.6%; 
anti-Kpa: 1.7% 
None
Thakral et al., India5 Case report Anti-K None
Arora et al., India6 Case report Anti-C Anti-K in same patient None
Merianou et al., Greece3 19.2% (23/120 showed  
a total of 50 antibodies)
Anti-C, anti-c, anti-Cw, and 
anti-E: 28%
Anti-K: 20% Anti-Fya,-Fyb: 10%;  
anti-Jka,-Jkb: 16%; anti-M: 6%; 
anti-S: 6%; anti-s: 2%;  
anti-Lea: 10%; anti-Leb: 2%
Sadeghian et al., Iran11 2.9% (9/313 showed a total 
of 12 antibodies all  
of Rh system)
Anti-D: 88.9%;  
Anti-C: 33.3%; and  
Anti-E: 11.1%
None None
Ameen et al., Kuwait12 30% (57/190 showed a 
total of 142 antibodies)
Anti-D: 21.1%;  
anti-C: 15.8%; anti-c: 8.8%; 
anti-E: 45.6%;  
anti-Cw: 8.8%
Anti-K: 72%; anti-Kpa: 5.3% Anti-Fya: 3.5%; anti-Fyb: 3.5%; 
anti-Jka: 10.5%; anti-Jkb: 1.8%; 
anti-S: 5.3%; anti-Lea: 12.3%; 
anti-Leb: 3.5%; anti-Lua:1.8%
Singer et al., United 
States13
22% (14/64 showed a total 
of 19 antibodies)
Anti-E: 21%; anti-c: 10% Anti-K: 31%; anti-Kpa: 5.2% anti-Jkb, anti-M, anti-Lea, anti-I, 
anti-HTLA: 5.2% each
Spanos et al., Italy14 18% (220/1200 showed a 
total of 470 antibodies)
 anti-D: 4.3%; anti-C: 4.7%; 
anti-Cw: 5.7%; anti-c: 4%; 
anti-E: 14%; anti-e: 1.3%
Anti-K: 28.5%;  
anti-Kpa: 1.3%
 anti- M: 2.1%; anti-N: 0.4%; 
anti-S: 4.9%; anti-s: 0.4%; 
anti-Jka: 3.8%; anti-Jkb: 4.3%; 
anti-Lea: 4.3%; anti-Leb: 1.7%; 
anti-Fya: 2.8%; anti-Fyb: 1.3%; 
anti-P1: 1.3%; anti-A1: 0.9%; 
anti-Sda: 0.6%; anti-Lua: 0.4%; 
anti-H: 0.2%; anti-Dia: 0.2%
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hemolytic transfusion reactions. The policy should preferably 
be adopted irrespective of financial constraints as it will pave 
the way for better transfusion practices and reduce the risk of 
adverse reactions in patients who are transfusion dependent. 
In addition, once the patient develops alloantibodies, a 
special immunohematology report indicating the nature of 
the antibody should be provided to the patient for all future 
transfusions.
The adoption of such a policy in multiply transfused 
patients in developing countries will definitely lead to added 
expenses on the part of transfusion services. However, 
when compared with the risk of alloimmunization and the 
resulting complications of transfusion therapy, the benefits 
of such a policy outweigh the added financial burden. Once 
alloantibodies are formed, the risk of adverse transfusion 
reaction increases, which can increase the hospital stay of 
patients and decrease their transfusion interval. Further, 
multiple crossmatches may be required, which again means 
an increased cost levied on the patient and the hospital service. 
Hence, the implementation of such a stringent policy would 
ultimately lead to more systematic follow-up of patients and a 
better quality of life.
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